New Jersey drugmaker to chop 69 opioid gross sales jobs

The corporate will eradicate its gross sales pressure within the U.S. serving the MorphaBond ER product, an prolonged reduction morphine remedy. The corporate will proceed to promote the drug, however it’s going to accomplish that and not using a devoted gross sales pressure. 

“We’re making this variation to focus our assets and vitality on our oncology pipeline and our iron enterprise,” an unnamed spokesperson advised ROI-NJ. “We’re proud and grateful of the trouble by our subject gross sales groups and thank them for his or her dedication to sufferers and the suppliers who take care of them.”

Extra articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy

© Copyright ASC COMMUNICATIONS 2019. All for LINKING to or REPRINTING this content material? View our insurance policies by clicking here.